Alexion Pharmaceuticals (ALXN) reported quarterly earnings results on Thursday, Apr-28-2016. The company reported $1.11 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $1.13. The company posted revenue of $701.00 million in the period, compared to analysts expectations of $711.95 million. The company’s revenue was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Shares were Downgraded by Robert W. Baird on Mar 8, 2016 to ” Neutral” and Lowered the Price Target to $ 170 from a previous price target of $221 .Citigroup Initiated Alexion Pharmaceuticals on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $165.Shares were Reiterated by UBS on Feb 4, 2016 to “Buy” and Lowered the Price Target to $ 200 from a previous price target of $222 .
Alexion Pharmaceuticals closed down -3.23 points or -2.10% at $150.78 with 18,65,581 shares getting traded on Wednesday. Post opening the session at $154.47, the shares hit an intraday low of $150.75 and an intraday high of $155.48 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 5, 2016, David Hallal (CEO) sold 1,414 shares at $136.04 per share price. According to the SEC, on Mar 4, 2016, Julie O’neill (EVP. Global Operations) sold 651 shares at $149.55 per share price. On Mar 1, 2016, Heidi L Wagner (SVP, Global Government Affairs) sold 547 shares at $138.91 per share price, according to the Form-4 filing with the securities and exchange commission.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.